What is the name of the staging system used for endometrial cancer?

The staging system used for endometrial cancer is known as FIGO, which stands for the International Federation of Gynecology and Obstetrics. This system is specifically designed to provide a standardized method for categorizing the extent of endometrial cancer progression, allowing for consistency in diagnosis, treatment planning, and outcome comparison across different clinical settings.

FIGO's staging system is based on the depth of tumor invasion into the myometrium, the extent of disease spread to regional lymph nodes, and any distant metastases. It helps clinicians and researchers communicate more effectively about the disease's characteristics and severity, guiding treatment decisions and prognostication.

Other options, although notable in cancer staging and treatment guidelines, are tailored for different uses: the AJCC (American Joint Committee on Cancer) provides a comprehensive system for various cancer types but is not specifically tailored to endometrial cancer; NCCN (National Comprehensive Cancer Network) focuses on clinical practice guidelines; SEER (Surveillance, Epidemiology, and End Results Program) gathers data on cancer incidence and survival, but does not serve as a staging system. Thus, FIGO is distinctly recognized for staging endometrial cancer.